Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Kirk R. Schultz; W. Paul Bowman; Alexander Aledo; William B. Slayton; Harland N. Sather; Meenakshi Devidas; Chenguang Wang; Stella M. Davies; Paul S. Gaynon; Michael E. Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew J. Carroll; Nyla A. Heerema; Naomi Winick; Michael J. Borowitz; Stephen P. Hunger; William L. Carroll; Bruce M. Camitta

doi:10.1200/jco.2008.21.2514

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Imatinib plus intensive chemotherapy improved 3-year EFS in children and adolescents with Ph+ ALL, with no appreciable increase in toxicity. BMT plus imatinib offered no advantage over BMT alone. Additional follow-up is required to determine the impact of this treatment on long-term EFS and determine whether chemotherapy plus imatinib can replace BMT.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schultz et al. (2009) studied this question.

synapsesocial.com/papers/69d819f9b5518339b2ae2cc9 https://doi.org/10.1200/jco.2008.21.2514

View Full Paper

Ask AI

Bookmark

Share

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Ask about this paper

Abstract

Discussion

Cite This Study

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading